CRPC is a stage of prostate cancer which is attracting more and more interest in the urological community. It is a stage of the disease in which the tumour becomes independent from hormone-blocking therapy. Fortunately we have two medicines at our disposal (Abiraterone and Enzalutamide) in our country for this phase of the illness before the patient comes to the oncologist.
The main advantage of these medicines is the improvement in terms of the overall survival and significant progress in the performance status of the patient.
Currently, the patients with a tumour which is resistant to castration levels, metastatic (principally of the bone) and asymptomatic or scarcely symptomatic are the objective of these new treatments.
In our province, there are centres which have great experience in the use of these medicines. However, unfortunately, the Campo de Gibraltar area is a bit behind in this matter, as it is with other aspects of urology. From my point of view, the key factor here, as in many other instances, is interest and training.
From this December, I am starting using these new treatments. It is also worth mentioning the pharmaceutical industry, whose support helps scientific progress.